|

Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors

RECRUITINGN/ASponsored by Beijing Tiantan Hospital
Actively Recruiting
PhaseN/A
SponsorBeijing Tiantan Hospital
Started2024-01-25
Est. completion2026-09-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06164314

Summary

Neurosurgery is a risk factor for delirium. Dexmedetomidine might reduce delirium by reducing neuroinflammation, improving postoperative analgesia and sleep quality. The the primary hypothesis is that perioperative administration of dexmedetomidine can reduce the incidence of postoperative delirium

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients with temporal glioma scheduled for a elective craniotomy
* Age ≥18 years
* Obtain written informed consent.

Exclusion Criteria:

* Patients with severe preoperative cognitive impairment
* History of traumatic brain injury or previous neurosurgery
* History of psychotropic medications
* Allergy to dexmedetomidine
* Pregnant or lactating women
* History of obstructive sleep apnoea syndrome
* Severe bradycardia(heart rate \<40 beats/min), sick sinus syndrome or second-to-third degree atrioventricular block
* Severe hepatic dysfunction
* Severe renal dysfunction

Conditions2

CancerPostoperative Delirium

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.